AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | Natera(NTRA)saw insider trading activity on 11/3/2025
ByAinvest
Monday, Nov 3, 2025 11:00 pm ET1min read
Natera(NTRA) saw insider trading activity on 11/3/2025, there were 7 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 11/3/2025 | CEO AND PRESIDENT | Chapman Steven Leonard | Sell | 1915 | 198.96 | 381.01k |
| 11/3/2025 | CEO AND PRESIDENT | Chapman Steven Leonard | Buy | 3595 | 20.27 | 72.87k |
| 11/3/2025 | CEO AND PRESIDENT | Chapman Steven Leonard | Buy | 150000 | 119.75 | 17962.5k |
| 11/3/2025 | CEO AND PRESIDENT | Chapman Steven Leonard | Sell | 2215 | 198.03 | 438.63k |
| 11/3/2025 | CEO AND PRESIDENT | Chapman Steven Leonard | Sell | 156573 | 200.00 | 31314.33k |
| 11/3/2025 | EXECUTIVE CHAIRMAN | Rabinowitz Matthew | Sell | 17100 | 200.00 | 3420.0k |
| 11/3/2025 | CEO AND PRESIDENT | Chapman Steven Leonard | Buy | 2084 | 13.01 | 27.11k |
| 10/29/2025 | CO-FOUNDER | Sheena Jonathan | Sell | 288 | 192.32 | 55.39k |
| 10/29/2025 | CHIEF FINANCIAL OFFICER | Brophy Michael Burkes | Sell | 300 | 188.37 | 56.51k |
| 10/29/2025 | CHIEF FINANCIAL OFFICER | Brophy Michael Burkes | Sell | 667 | 190.99 | 127.39k |
[Company Profile]
Natera, Inc. were incorporated in Delaware in January 2007. The company is a diagnostics company with proprietary molecular and bioinformatics technology that the company is applying to change the management of disease worldwide. The company cell-free DNA, or cfDNA, technology combines novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with statistical algorithms which incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. The company aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier and more targeted interventions that help lead to longer, healthier lives.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet